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Abstract 
Background: Herbal remedies are used worldwide and with an increasing popularity in Western countries. 
Although often perceived as “naturally safe”, herbals may cause severe adverse drug reactions (ADR), and 
particularly immediate-type allergic reactions can be life threatening. 
Objectives: Analyses of allergy-like immediate ADR to herbals documented in VigiBase®, the WHO 
international pharmacovigilance database. 
Methods: All suspected ADR in association with herbal exposure reported to VigiBase® from 1969 to 
August 2014 were retrieved. Among those all reports where WHOART reaction terms were indicative of 
acute allergic reactions, classified as “suspect” with a documented causality assessment and latency time of 
≤1 day were selected. For the most frequent specific herbal-ADR combinations the information component 
(IC) as a measure of disproportionality based on Bayesian statistics was calculated. 
Results: We identified 757 reports with 1,039 ADR. Products with mixed herbals (36.0%) and oral 
administration (63.2%) were predominant. The most frequent reactions were urticaria and rash (49.2%). 
Anaphylactic reactions accounted for 9.5%. We found disproportionally frequent reporting of mouth 
oedema (IC=1.81) and anaphylactic reactions (IC=1.24) with Phleum pratense.  
Conclusion:  
Our findings indicate that herbal medicines for oral use carry a risk for allergy-like immediate ADR. 
Studies using the Vigibase® database can identify specific combinations of particular herbs and adverse 
reactions. Health care professionals and patients should be aware of these risks and report any serious 
adverse experiences. 
Keywords 
adverse drug reactions, allergy, hypersensitivity, drug safety, herbal medicine, pharmacovigilance, 
phytotherapy. 
Key messages 
• While herbal products for oral use are generally regarded as safe, international pharmacovigilance 
data indicate that many such products carry a risk for acute allergy-like adverse reactions.  
• The recognition of the occurrence of such reactions with specific products is needed for their 
timely diagnosis as well as for prevention. 
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1 Introduction 
There is an increased prevalence in use of herbal medicines among the adult population in many western 
countries [1-3]. The most recent 2012 US National Health Interview Survey showed that 18% of adults 
used natural products including herbal medicine during the past 12 months [3]. The public often considers 
herbal products as safe since they are natural and is unaware that Complementary and Alternative 
Medicines (CAM) are not tested by regulatory agencies for their safety and efficacy [4]. In most countries, 
herbal medicines are defined as dietary supplements and as such do not have to meet pre- and 
postmarketing drug policy regulations [5]. However, use of herbal medicines can be associated with 
development of severe adverse reactions as a result of complex chemistry of herbals as well as their 
inappropriate use and a lack of quality control [6, 7]. In addition, patients may not disclose self-medication 
with herbal medicines to their health care professionals, and even if they do there may be limited 
knowledge of their potential adverse reactions and interactions with concomitantly used prescription drugs 
[8, 9]. 
In the absence of comprehensive systematic safety evaluations of herbal medicines, spontaneous reporting 
systems of adverse drug reactions (ADR) play a major role for their worldwide safety surveillance and 
signal detection [10]. Although there are many case reports of ADR associated with herbals in the 
literature, the majority of reports are documented in large pharmacovigilance databases, and those valuable 
resources should be systematically analyzed for ADR associated with herbals [7, 11, 12].  ADR to herbals 
cover a wide range of manifestations that are mostly mild and followed by full recovery. However, 
immediate-type allergic reactions are also a typical, potentially life threatening and therefore clinically 
most relevant adverse reaction to herbal products. Therefore, we conducted a study that aimed to 
investigate the reporting patterns and characteristics of immediate allergic adverse reactions associated with 
herbal medicines in international pharmacovigilance. 
 
2 Methods  
2.1 Study settings 
VigiBase®, the largest international pharmacovigilance database of spontaneous ADR reports was the 
source of our reports. VigiBase® is maintained by the Uppsala Monitoring Centre (UMC) in association 
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with the World Health Organization’s (WHO) international pharmacovigilance program. The UMC is an 
independent foundation and a center for international service and scientific research. It collaborates with 
118 member countries around the world that collect and evaluate spontaneous ADR reports [13]. These 
centers forward anonymized ADR reports received from various primary reporting sources to the UMC in a 
standardized format, containing structured information on adverse events, involved patients and drugs 
including standardized semi-quantitative causality assessments [14].  
The database of the UMC, Vigibase currently contains over 9 million case reports. The WHO Adverse 
Drug Reaction Terminology (WHOART) and WHO Drug Dictionary/WHO Herbal Dictionary are used for 
coding of clinical information in relation to drug therapy and reported drugs on the reports [13].  MedDRA 
terminology has been made the standard in VigiBase for several years, and there are automated algorithms 
that convert codes form those two dictionaries in both directions. Herbal medicine refers to herbs, herbal 
materials, herbal preparations and finished herbal products. Herbal products are assigned herbal 
anatomical-therapeutic-chemical (HATC) codes specifying their therapeutic use according to the 
Guidelines for Herbal ATC classification [15]. HATC classification aggregates herbal remedies according 
to their medical uses that have been found in the literature and does not indicate that the remedy has been 
proven as effective or safe [13]. Herbal pharmacovigilance terminology is used in accordance with WHO 
guidelines [16]. 
 
2.2 Study design and selection of cases 
A flowchart of the study design and case selection process is presented in Fig. 1. The aim of our study was 
to focus on immediate-type allergic ADR associated with herbals, because those are potentially life 
threatening and therefore clinically highly relevant. The level of documentation within VigiBase® is 
heterogeneous, and it may be difficult to make an exact medical diagnosis based on the available 
information. With this limitation in mind we defined case selection criteria that are likely indicators of 
immediate-type allergic reactions (see Table 2 for a listing of included WHOART terms). Because 
VigiBase® does not allow for a validation of type 1 immediate hypersensitivity reactions according to 
comprehensive clinical diagnostic criteria we carefully refer to included cases as “allergy-like immediate 
reactions” in our study. For inclusion in the study population we used the following inclusion criteria: 
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exposure to manually validated herbal products, which must be classified by the primary reporter as 
“suspect” with regard to the reported ADR; documented causality assessment between herbal product and 
ADR classified as “possible”, “probable” or “certain”; documented latency time from herbal exposure to 
ADR onset of no more than one day; manual selection of WHO-ART preferred terms indicating an ADR 
that is a likely symptom of an immediate-type hypersensitivity reaction. In contrast, reaction terms that are 
compatible with but have a low specificity for immediate type allergic reactions such as cough, dyspnea, 
larynx pain, gastrointestinal symptoms or pruritus were on their own not considered sufficient for inclusion. 
Furthermore, we excluded ADR associated with the HATC term “herbal pollen not otherwise specified” 
from the main analysis because these are likely to refer to desensitization vaccines for the treatment of 
pollen allergies (ADR that may have a distinct special relationship to the indication for the suspected herbal 
products). ADR were also stratified over asthma-like reactions (defined by WHO-ART preferred terms 
“asthma”, “stridor” or “bronchospasm”) vs. all other ADR terms with high specificity for immediate-type 
allergic reactions. 
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Fig. 1: Flowchart of study design and case selection process  
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2.3 Statistical analysis 
Descriptive statistics was used to analyze case report characteristics. The unexpected ADR to herbals was 
quantitatively analysed using the Bayesian Confidence Propagation Neural Network methodology 
(BCPNN), a data-mining technique used for the detection of new signals in spontaneous reporting of ADR 
[17]. The measure of disproportionality expressed as the Information Component (IC) is used to indicate 
the frequency of specific drug-ADR combination that occurs more frequently in the database than expected 
in relation to the number of all reports with the particular drug and ADR and the total number of reports in 
the database. The IC is a logarithmic measure of association and is calculated as IC = log2 p(x,y) / ( p(x) * 
p(y) ), where: p(x) = probability of a specific drug x is listed on a case report; p(y) = probability of a 
specific drug-ADR combination x and y is listed on a case report; p(x,y) = probability of a specific drug x 
is listed on a case report.  
An IC of 0 results from drug-ADR combinations for which the number of observed cases is the 
same as that which might be expected from the overall reporting in the data set. Accordingly, an IC above 0 
indicates that a specific drug-ADR combination occurs more frequently in the dataset than expected from 
the background of the database. For the IC analysis we used the dataset of all reports that met our inclusion 
criteria and calculated the IC for all specific combinations that occurred with a frequency of 10 or more. 
Data management and analyses were performed using STATA Version 13.1 (StataCorp LP, College 
Station, TX, USA). 
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3 Results   
The initial dataset extracted from VigiBase® comprised 26,909 unique ADR reports with documented 
exposure to herbal products. These reports were received between 1969 and August 2014. After application 
of exclusion criteria 757 unique reports remained with 1,039 ADR (more than one reaction term can be 
reported per case) related to herbal products for the analyses (Fig. 1). The chronology for receipt of those 
reports is presented in Fig. 2, showing a pronounced increase of the reporting frequency in recent years. 
More than 50% of all included reports came from only three countries, i.e. Germany (22.3%), Australia 
(14.9%) and Thailand (11.2%). The most frequent primary reporters were physicians (32.1%), followed by 
hospitals (24.7%) and pharmacists (14.1%). 
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Fig. 2: Reporting frequency over time for all 757 included cases with allergy-like immediate adverse 
reactions during the use of herbals  
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3.1 Patients’ characteristics 
Patient demographics and reporting information of the 757 included reports are presented in Table 1. 
Women were overrepresented among included cases (68.6%), and more than one third of cases fell into the 
age category from 18 to 44 years.  
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Table 1:  Demographics of unique reports/patients of allergy-like immediate adverse reactions during the 
use of herbal remedies (N=757) 
 n % 
   
Gender   
   Female 519 68.6 
   Male 225 29.7 
   Not specified 13 1.7 
   
Age group (years)   
   <18 109 14.4 
   18 - 44 278 36.7 
   45 - 64 199 26.3 
   ≥ 65 117 15.5 
   Not specified 54 7.1 
   
Reporting country   
   Germany 169 22.3 
   Australia 113 14.9 
   Thailand 100 13.2 
   South Korea 49 6.5 
   Spain 43 5.7 
   Sweden 39 5.2 
   Switzerland 37 4.9 
   Cuba 29 3.8 
   United Kingdom 17 2.3 
   Malaysia 16 2.1 
   New Zealand 15 2.0 
   Norway 11 1.5 
   Other (<10 reports per country) 119 15.7 
   
Reporting source   
   Physician 243 32.1 
   Hospital 187 24.7 
   Pharmacist 107 14.1 
   Manufacturer 38 5.0 
   Consumer / non health professional 14 1.9 
   Other / not specified 168 22.2 
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3.2 Allergy-like immediate reactions 
Characteristics of allergy-like immediate reactions under herbal remedies are presented in Table 2 along 
with stratifications over the three given causality categories. The likelihood of a causal connection in the 
1,039 reported ADR had been assessed as “possible”, “probable” and “certain” in 59.2%, 32.2% and 8.6%, 
respectively. Outcome was favorable with recovery in 77.7% of all ADR, and there were no lethal cases. 
One should note however that there was no information available on the outcome for 9.2%. Asthma-like 
reactions accounted for only 4.8% of all ADR. The most commonly reported allergy-like immediate 
adverse reactions associated with herbals were “rash” (16.2%), “urticaria” (15.3%) and “rash 
erythematous” (13.4%). Anaphylactic and anaphylactoid reactions accounted altogether for 9.5% of 
reported ADR (anaphylactic reaction 4.5%, anaphylactic shock 2.8%, anaphylactoid reaction 2.2%), and 
Table 2 shows other serious ADR such as bronchospasm or larynx oedema. 
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Table 2: Characteristics of allergy-like immediate reactions during the use of herbal remedies (N=757) 
 Causality Overall 
 Possible Probable Certain   
 n % n % n % n % 
         
Total number of reported ADR 
 
615 59.2 335 32.2 89 8.6 1039 100 
         
Outcome          
   Recovered 431 70.1 296 88.4 80 89.9 807 77.7 
   Not recovered (yet) 97 15.8 18 5.4 4 4.5 119 11.5 
   Recovered with sequelae 10 1.6 7 2.1 - - 17 1.6 
   Died - - - - - - - - 
   Unknown / Not specified 77 12.5 14 4.2 5 5.6 96 9.2 
         
Type of ADR a          
   Allergic 584 95.0 319 95.2 86 96.6 989 95.2 
   Asthma-like 31 5.0 16 4.8 3 3.4 50 4.8 
         
Specification of reported ADR a 
(WHOART b preferred term) 
 
        
   Rash 108 17.6 53 15.8 7 7.9 168 16.2 
   Urticaria 86 14.0 57 17.0 16 18.0 159 15.3 
   Rash erythematous 91 14.8 37 11.0 11 12.4 139 13.4 
   Allergic reaction 42 6.8 13 3.9 3 3.4 58 5.6 
   Angioedema 27 4.4 21 6.3 5 5.6 53 5.1 
   Flushing 29 4.7 15 4.5 4 4.5 48 4.6 
   Anaphylactic reaction 28 4.6 10 3.0 9 10.1 47 4.5 
   Face oedema 34 5.5 10 3.0 2 2.3 46 4.4 
   Rash maculo-papular 23 3.7 21 6.3 - - 44 4.2 
   Oedema mouth 14 2.3 14 4.2 10 11.2 38 3.7 
   Oedema periorbital 24 3.9 9 2.7 3 3.4 36 3.5 
   Anaphylactic shock 11 1.8 15 4.5 3 3.4 29 2.8 
   Bronchospasm 14 2.3 11 3.3 1 1.1 26 2.5 
   Anaphylactoid reaction 11 1.8 8 2.4 4 4.5 23 2.2 
   Tongue oedema 12 2.0 6 1.8 3 3.4 21 2.0 
   Asthma 11 1.8 5 1.5 2 2.3 18 1.7 
   Dermatitis contact 5 0.8 8 2.4 3 3.4 16 1.5 
   Dermatitis 6 1.0 7 2.1 1 1.1 14 1.4 
   Oedema pharynx 4 0.7 6 1.8 1 1.1 11 1.1 
   Oedema generalised 5 0.8 4 1.2 - - 9 0.9 
   Eosinophilia 8 1.3 - - - - 8 0.8 
   Allergy 6 1.0 - - 1 1.1 7 0.7 
   Larynx oedema 4 0.7 3 0.9 - - 7 0.7 
   Stridor 5 0.8 - - - - 5 0.5 
   Erythema multiforme 3 0.5 - - - - 3 0.3 
   Skin reaction localised 2 0.3 - - - - 2 0.2 
   Bronchospasm aggravated 1 0.2 - - - - 1 0.1 
   Drug hypersensitivity syndrome - - 1 0.3 - - 1 0.1 
   Purpura allergic - - 1 0.3 - - 1 0.1 
   Urticaria acute 1 0.2 - - - - 1 0.1 
         
a ADR, adverse drug reactions; b WHOART, The WHO Adverse Reactions Terminology 
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3.3 Suspect Herbals  
Descriptions of specific herbals associated with reported ADR and their route of administration are 
presented in Table 3. Preparations that contained a mixture of several herbals were the suspected cause in 
36% of all ADR and therefore by far the most frequently reported herbal products in association with ADR, 
followed by Phleum pratense (common name: Timothy grass, 6.5%), Andrographis paniculata (several 
common names including kalmegh, 5.0%), Echinacea purpurea (3.8%) and Ginkgo biloba (3.6%). Oral 
administrations accounted for almost two thirds of ADR, followed by topical / cutaneous and sublingual 
administrations in 9.0% and 6.4%, respectively. 
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Table 3: Characteristics of administered herbal remedies associated with allergy-like immediate reactions 
(N=757) 
 Causality Overall 
 Possible Probable Certain   
 n % n % n % n % 
         
Total number of reported ADR a 
 
615 59.2 335 32.2 89 8.6 1039 100 
         
Herbs reported in association with ADR a 
 
        
   Mixed herbals 220 35.8 126 37.6 28 31.5 374 36.0 
   Phleum pratense 16 2.6 25 7.5 27 30.3 68 6.5 
   Andrographis paniculata 27 4.4 25 7.5 - - 52 5.0 
   Echinacea purpurea 30 4.9 6 1.8 3 3.4 39 3.8 
   Ginkgo biloba 29 4.7 6 1.8 2 2.3 37 3.6 
   Hedera helix 25 4.1 4 1.2 1 1.1 30 2.9 
   Plantago ovata 6 1.0 9 2.7 4 4.5 19 1.8 
   Hypericum perforatum 13 2.1 4 1.2 1 1.1 18 1.7 
   Viscum album 13 2.1 4 1.2 1 1.1 18 1.7 
   Valeriana officinalis 10 1.6 6 1.8 1 1.1 17 1.6 
   Cimicifuga racemosa 11 1.8 5 1.5 - - 16 1.5 
   Mentha x piperita 6 1.0 9 2.7 1 1.1 16 1.5 
   Other (<15 ADR per herbal) 209 34.0 106 34.0 20 22.5 335 32.4 
         
Administration route of reported herbal 
   
      
   Oral 394 64.1 234 69.9 29 32.6 657 63.2 
   Topical / cutaneous 57 9.3 26 7.8 10 11.2 93 9.0 
   Sublingual 18 2.9 21 6.3 27 30.3 66 6.4 
   Intravenous 29 4.7 6 1.8 4 4.5 39 3.8 
   Subcutaneous 11 1.8 12 3.6 6 6.7 29 2.8 
   Other (≤10 ADR per route) 38 6.2 14 4.2 6 6.7 58 5.6 
   Not specified 68 11.1 22 6.6 7 7.9 97 9.3 
         
a ADR, adverse drug reactions         
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3.4 Disproportionality analysis 
Calculations of IC values for all 16 specific herbal / allergy-like reaction combinations that had been 
reported at least 10 times are presented in Table 4. Accordingly, significantly higher frequencies than 
expected by chance were found for Phleum pratense (Timothy grass) linked to oedema of the mouth (IC= 
1.81, 95%CI 0.67-2.86) and to anaphylactic reactions (IC= 1.23, 95%CI 0.03-2.33). 
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Table 4: Most frequently reported (N≥10) specific combinations of herbal remedies and allergic reactions 
with their IC values 
 
Herbal remedy WHOART b preferred term N 
reports 
% IC a (95% CI) 
      
Mixed herbals Rash 75 (7.2) -0.15 (-0.60 - 0.30) 
Mixed herbals Urticaria 58 (5.6) -0.44 (-0.93 - 0.04) 
Mixed herbals Rash erythematous 36 (3.5) -0.93 (-1.53 - -0.36) 
Mixed herbals Face oedema 21 (2.0) -0.11 (-0.95 - 0.68) 
Mixed herbals Allergic reaction 20 (1.9) -0.52 (-1.35 - 0.26) 
Mixed herbals Rash maculo-papular 20 (1.9) -0.12 (-0.98 - 0.70) 
Mixed herbals Oedema mouth 19 (1.8) 0.02 (-0.88 - 0.87) 
Mixed herbals Anaphylactic reaction 15 (1.4) -0.63 (-1.59 - 0.26) 
Mixed herbals Angioedema 15 (1.4) -0.80 (-1.76 - 0.07) 
Mixed herbals Flushing 15 (1.4) -0.66 (-1.62 - 0.22) 
Mixed herbals Anaphylactoid reaction 12 (1.2) 0.08 (-1.08 - 1.16) 
Phleum pratense Oedema mouth 12 (1.2) 1.81 (0.67 - 2.86) 
Andrographis paniculata Urticaria 11 (1.1) 0.01 (-1.11 - 1.01) 
Mixed herbals Oedema periorbital 11 (1.0) -0.69 (-1.83 - 0.33) 
Mixed herbals Anaphylactic shock 10 (1.0) -0.52 (-1.74 - 0.58) 
Phleum pratense Anaphylactic reaction 10 (1.0) 1.24 (0.03 - 2.33) 
      
a IC, information component; b WHOART, The WHO Adverse Reactions Terminology 
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4 Discussion  
We report on a series of 757 case-reports indicative of allergy-like adverse reactions during the use of 
herbal remedies from the Vigibase of spontaneous ADR reports coming from 42 countries since 1969. Our 
study documents that a large number of different herbal remedies cause immediate allergy-like reactions in 
the population. Among all reports, mixed herbals, Phleum pratense and Andrographis paniculata were 
most frequently reported in association with ADR. Andrographis paniculata is well known in Ayurveda 
medicine and typically used for the treatment of common cold. Previously reported findings from Thailand 
investigating the safety of Andrographis paniculata showed a similar range of hypersensitivity reactions 
ranging from skin reactions to anaphylaxis [18]. Case-reports indicative of hypersensitivity to other most 
frequently reported herbals in our study have been published previously [19-24]. 
High proportion of reports concerned women between the age of 18 and 44. The most frequently 
reported manifestations of allergy-like immediate reactions were skin reactions, and also anaphylactic / 
anaphylactoid reactions most frequently observed after oral administration. Such severe ADR are rarely 
seen after oral use of herbals. The occurrence of allergic reactions is rather more likely to be expected after 
cutaneous and mucosal exposure, a known risk factor for sensitization to allergens. It is reasonable to 
assume that rather easy to diagnose reactions with a short time to onset and skin manifestations as well as 
serious reactions are more frequently reported compared to other reactions. Oral administration of herbals 
in females may be most common in the population. Such observation is often made in CAM/herbal use 
prevalence studies [1-3]. It is therefore expected that this population is also overrepresented in all included 
reports. A higher reporting rate of ADR by females could be another factor contributing to such pattern 
[25]. On the other hand, a higher proportion of females experiencing an adverse reaction in our study may 
confirm results of other studies where a higher incidence of hypersensitivity reaction in females compared 
to males was found [26, 27]. Nevertheless, this finding does not allow conclusions regarding the role of 
those characteristics as risk factors although they are further discussed in the literature.  
Asthma-like reactions were found in 4.8% of reports. Some commonly used herbals display a 
wide spectrum of cross-reactivity to other common inhalation or food allergens. Therefore a preexisting 
diagnosis of asthma and other atopic diseases may be a risk factor for the development of allergic 
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reactions to herbals.  There is a relevant incidence of herbal use among patients with known allergies [28]. 
For example, herbal medicine was shown to be the third popular choice among patients suffering from 
asthma with a prevalence of 60-70% in patients with a history of moderate or severe asthma in the United 
Kingdom [29]. These findings imply that in the presence of known atopic diseases health professionals and 
patients should only use herbals with great care in order to prevent severe allergic reactions to herbals in 
this special population.           
 Other relevant factors that were not recorded and could have contributed to the development of 
allergy-like reactions could have been user's genetics, nutrition status, concurrent medication, disease states 
(e.g.: food allergies) and exercise induced anaphylaxis. Also, unrecognized herbal-drug interactions could 
result in a lack of allergy control and manifestation of allergy symptoms. 
Strengths of our study include the international collection of reports from 42 countries over more than four 
decades and the use of standardized HATC drug classification, WHOART nomenclature and formal 
causality assessment for adverse reactions. At the same time it is important to recognize special 
characteristics and inherent limitations of this data source for the study design and interpretation of 
findings. Most important, spontaneous reporting data do not provide information on the actual exposure to 
herbals in a population or on the incidence of related ADR. Therefore, qualitative descriptive analyses and 
signal detection for previously unknown drug safety issues are the primary strength of spontaneous 
reporting systems rather than quantitative analyses. Furthermore, the level of documentation in VigiBase® 
is heterogeneous, the extracted reports do not contain original detailed free-text descriptions by the primary 
reporters, and particularly for early reports formal causality assessment may not be available requiring 
exclusion from our study population. One must also realize that a standardized reaction term has many 
advantages, but it is not the same as a clinical diagnosis based on established clinical diagnostic criteria 
[30]. In light of those limitations we used a restrictive study design emphasizing high specificity with 
regard to the likely diagnosis of immediate-type allergic reactions and consequently excluded the majority 
of reports from the extracted original raw dataset. Such a conservative approach implies reduced sensitivity 
for signal detection, but we believe that overall it improves the interpretability of our findings.   
 There are several other challenges that pharmacovigilance studies investigating risks associated 
with herbal remedies face in general. As a result of insufficient herbal product regulations, some ADR may 
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be attributable to a lack of standardization, contamination, adulteration, plant misidentification/substitution, 
improper use of herbal medicines including their inappropriate labeling rather than 
pharmacological/toxicology effects of herbals [5-7, 31]. Also, implementation of innovative preparation 
methods of traditionally used herbal remedies may alter pharmacological/toxicological properties of herbs 
and lead to their toxicity rather than therapeutic use. In the era of market globalization, the knowledge of 
traditional preparation and use of herbals is therefore necessary given the increase in use of traditional 
herbal remedies outside of their culture of origin.   
An estimate of the frequency of ADR to herbals is not possible based on analyses of spontaneous reporting 
data, but we must assume that our findings represent only the “tip of the iceberg” regarding safety issues 
with herbal remedies [10]. Moreover, underreporting of adverse events particularly herbals by patients as 
well as health care professionals is high and health care professionals are not always aware of potential 
safety issues associated with herbal use [8-10, 32, 33].  
 In summary, any pharmacologically active product including herbal has the potential to cause 
harm. We found that herbal medicines for oral use carry a risk for allergy-like immediate ADR and that 
studies using the WHO-UMC pharmacovigilance database can identify specific associations between 
particular herbals and adverse reactions. As the prevalence of herbal use is increasing, health care 
professionals as well as patients need to become better informed about the possible risks associated with 
herbal medicines. When health care professionals take drug histories they should actively ask their patients 
also about all self-administered herbal remedies and dietary supplements. Further studies are needed to 
establish associations and risk factors that are related to herbal use and allergic reactions. 
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